Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2021 |
| Outros Autores: | , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Institucional da UFMG |
| Texto Completo: | https://doi.org/10.3389/fphar.2021.557962 http://hdl.handle.net/1843/61924 https://orcid.org/0000-0002-2589-0332 https://orcid.org/0000-0003-1032-4255 https://orcid.org/0000-0002-6119-6049 https://orcid.org/0000-0003-4486-1518 https://orcid.org/0000-0002-5568-5997 https://orcid.org/0000-0002-2535-2737 https://orcid.org/0000-0001-8102-7720 https://orcid.org/0000-0002-0804-5196 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0003-1038-2324 https://orcid.org/0000-0002-6944-3008 https://orcid.org/0000-0002-9950-1707 https://orcid.org/0000-0001-9483-4206 |
Resumo: | CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico |
| id |
UFMG_ef1faeebe9f95b4369ec73ed2aace813 |
|---|---|
| oai_identifier_str |
oai:repositorio.ufmg.br:1843/61924 |
| network_acronym_str |
UFMG |
| network_name_str |
Repositório Institucional da UFMG |
| repository_id_str |
|
| spelling |
2023-12-12T17:49:29Z2023-12-12T17:49:29Z202112https://doi.org/10.3389/fphar.2021.5579621663-9812http://hdl.handle.net/1843/61924https://orcid.org/0000-0002-2589-0332https://orcid.org/0000-0003-1032-4255https://orcid.org/0000-0002-6119-6049https://orcid.org/0000-0003-4486-1518https://orcid.org/0000-0002-5568-5997https://orcid.org/0000-0002-2535-2737https://orcid.org/0000-0001-8102-7720https://orcid.org/0000-0002-0804-5196https://orcid.org/0000-0001-7656-1849https://orcid.org/0000-0003-1038-2324https://orcid.org/0000-0002-6944-3008https://orcid.org/0000-0002-9950-1707https://orcid.org/0000-0001-9483-4206CNPq - Conselho Nacional de Desenvolvimento Científico e TecnológicoFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas GeraisCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorINCT – Instituto nacional de ciência e tecnologia (Antigo Instituto do Milênio)The presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twenty-three hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPS-challenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.engUniversidade Federal de Minas GeraisUFMGBrasilICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIAICB - DEPARTAMENTO DE FARMACOLOGIAICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICAICB - DEPARTAMENTO DE MORFOLOGIAICX - DEPARTAMENTO DE QUÍMICAFrontiers in PharmacologyFarmacologia pulmonarAngiotensinaAsmaEosinófilosNeutrófilosAparelho respiratório -- DoençasResolution of inflammationEosinophilic inflammationNeutrophilic inflammationAllergic lung inflammationLPSRenin–angiotensin system 4Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthmainfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttps://www.frontiersin.org/articles/10.3389/fphar.2021.557962/fullGiselle Santos MagalhãesJuliana Fabiana GregórioArthur Tonani Pereira Cançado RibeiroIsis Felippe BaroniAna Victoria de Oliveira VasconcellosGabriela Pansanato NakashimaIsabel Fusaro Aguiar OliveiraNatália Alves de MatosThalles de Freitas CastroFrank Silva BezerraRubén Dario Sinisterra MillánVanessa PinhoMauro Martins TeixeiraRobson Augusto Souza SantosMaria da Glória Rodrigues-MachadoMaria José Campagnole dos Santosapplication/pdfinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGLICENSELicense.txtLicense.txttext/plain; charset=utf-82042https://repositorio.ufmg.br/bitstream/1843/61924/1/License.txtfa505098d172de0bc8864fc1287ffe22MD51ORIGINALOral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma.pdfOral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma.pdfapplication/pdf749680https://repositorio.ufmg.br/bitstream/1843/61924/2/Oral%20formulation%20of%20angiotensin-%281-7%29%20promotes%20therapeutic%20actions%20in%20a%20model%20of%20eosinophilic%20and%20neutrophilic%20asthma.pdf74a5a0bb20ed8a727bad317aba3e21a7MD521843/619242023-12-12 14:49:30.148oai:repositorio.ufmg.br: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Repositório de PublicaçõesPUBhttps://repositorio.ufmg.br/oaiopendoar:2023-12-12T17:49:30Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false |
| dc.title.pt_BR.fl_str_mv |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| title |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| spellingShingle |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma Giselle Santos Magalhães Resolution of inflammation Eosinophilic inflammation Neutrophilic inflammation Allergic lung inflammation LPS Renin–angiotensin system 4 Farmacologia pulmonar Angiotensina Asma Eosinófilos Neutrófilos Aparelho respiratório -- Doenças |
| title_short |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| title_full |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| title_fullStr |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| title_full_unstemmed |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| title_sort |
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma |
| author |
Giselle Santos Magalhães |
| author_facet |
Giselle Santos Magalhães Juliana Fabiana Gregório Arthur Tonani Pereira Cançado Ribeiro Isis Felippe Baroni Ana Victoria de Oliveira Vasconcellos Gabriela Pansanato Nakashima Isabel Fusaro Aguiar Oliveira Natália Alves de Matos Thalles de Freitas Castro Frank Silva Bezerra Rubén Dario Sinisterra Millán Vanessa Pinho Mauro Martins Teixeira Robson Augusto Souza Santos Maria da Glória Rodrigues-Machado Maria José Campagnole dos Santos |
| author_role |
author |
| author2 |
Juliana Fabiana Gregório Arthur Tonani Pereira Cançado Ribeiro Isis Felippe Baroni Ana Victoria de Oliveira Vasconcellos Gabriela Pansanato Nakashima Isabel Fusaro Aguiar Oliveira Natália Alves de Matos Thalles de Freitas Castro Frank Silva Bezerra Rubén Dario Sinisterra Millán Vanessa Pinho Mauro Martins Teixeira Robson Augusto Souza Santos Maria da Glória Rodrigues-Machado Maria José Campagnole dos Santos |
| author2_role |
author author author author author author author author author author author author author author author |
| dc.contributor.author.fl_str_mv |
Giselle Santos Magalhães Juliana Fabiana Gregório Arthur Tonani Pereira Cançado Ribeiro Isis Felippe Baroni Ana Victoria de Oliveira Vasconcellos Gabriela Pansanato Nakashima Isabel Fusaro Aguiar Oliveira Natália Alves de Matos Thalles de Freitas Castro Frank Silva Bezerra Rubén Dario Sinisterra Millán Vanessa Pinho Mauro Martins Teixeira Robson Augusto Souza Santos Maria da Glória Rodrigues-Machado Maria José Campagnole dos Santos |
| dc.subject.por.fl_str_mv |
Resolution of inflammation Eosinophilic inflammation Neutrophilic inflammation Allergic lung inflammation LPS Renin–angiotensin system 4 |
| topic |
Resolution of inflammation Eosinophilic inflammation Neutrophilic inflammation Allergic lung inflammation LPS Renin–angiotensin system 4 Farmacologia pulmonar Angiotensina Asma Eosinófilos Neutrófilos Aparelho respiratório -- Doenças |
| dc.subject.other.pt_BR.fl_str_mv |
Farmacologia pulmonar Angiotensina Asma Eosinófilos Neutrófilos Aparelho respiratório -- Doenças |
| description |
CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico |
| publishDate |
2021 |
| dc.date.issued.fl_str_mv |
2021 |
| dc.date.accessioned.fl_str_mv |
2023-12-12T17:49:29Z |
| dc.date.available.fl_str_mv |
2023-12-12T17:49:29Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/1843/61924 |
| dc.identifier.doi.pt_BR.fl_str_mv |
https://doi.org/10.3389/fphar.2021.557962 |
| dc.identifier.issn.pt_BR.fl_str_mv |
1663-9812 |
| dc.identifier.orcid.pt_BR.fl_str_mv |
https://orcid.org/0000-0002-2589-0332 https://orcid.org/0000-0003-1032-4255 https://orcid.org/0000-0002-6119-6049 https://orcid.org/0000-0003-4486-1518 https://orcid.org/0000-0002-5568-5997 https://orcid.org/0000-0002-2535-2737 https://orcid.org/0000-0001-8102-7720 https://orcid.org/0000-0002-0804-5196 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0003-1038-2324 https://orcid.org/0000-0002-6944-3008 https://orcid.org/0000-0002-9950-1707 https://orcid.org/0000-0001-9483-4206 |
| url |
https://doi.org/10.3389/fphar.2021.557962 http://hdl.handle.net/1843/61924 https://orcid.org/0000-0002-2589-0332 https://orcid.org/0000-0003-1032-4255 https://orcid.org/0000-0002-6119-6049 https://orcid.org/0000-0003-4486-1518 https://orcid.org/0000-0002-5568-5997 https://orcid.org/0000-0002-2535-2737 https://orcid.org/0000-0001-8102-7720 https://orcid.org/0000-0002-0804-5196 https://orcid.org/0000-0001-7656-1849 https://orcid.org/0000-0003-1038-2324 https://orcid.org/0000-0002-6944-3008 https://orcid.org/0000-0002-9950-1707 https://orcid.org/0000-0001-9483-4206 |
| identifier_str_mv |
1663-9812 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartof.pt_BR.fl_str_mv |
Frontiers in Pharmacology |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| dc.publisher.initials.fl_str_mv |
UFMG |
| dc.publisher.country.fl_str_mv |
Brasil |
| dc.publisher.department.fl_str_mv |
ICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA ICB - DEPARTAMENTO DE FARMACOLOGIA ICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICA ICB - DEPARTAMENTO DE MORFOLOGIA ICX - DEPARTAMENTO DE QUÍMICA |
| publisher.none.fl_str_mv |
Universidade Federal de Minas Gerais |
| dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMG instname:Universidade Federal de Minas Gerais (UFMG) instacron:UFMG |
| instname_str |
Universidade Federal de Minas Gerais (UFMG) |
| instacron_str |
UFMG |
| institution |
UFMG |
| reponame_str |
Repositório Institucional da UFMG |
| collection |
Repositório Institucional da UFMG |
| bitstream.url.fl_str_mv |
https://repositorio.ufmg.br/bitstream/1843/61924/1/License.txt https://repositorio.ufmg.br/bitstream/1843/61924/2/Oral%20formulation%20of%20angiotensin-%281-7%29%20promotes%20therapeutic%20actions%20in%20a%20model%20of%20eosinophilic%20and%20neutrophilic%20asthma.pdf |
| bitstream.checksum.fl_str_mv |
fa505098d172de0bc8864fc1287ffe22 74a5a0bb20ed8a727bad317aba3e21a7 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
| repository.name.fl_str_mv |
Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG) |
| repository.mail.fl_str_mv |
|
| _version_ |
1803589330565857280 |